Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)
NCT ID: NCT00421018
Last Updated: 2012-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
187 participants
INTERVENTIONAL
2006-11-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symptom-guided group
Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
Single corticosteroid inhalers and Singulair
Treatment steps according to preset algorithm
FeNO-guided group
Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
Single corticosteroid inhalers and Singulair
Treatment steps according to preset algorithm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single corticosteroid inhalers and Singulair
Treatment steps according to preset algorithm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of Asthma
* Glucocorticoid treatment \> 6 months.
* Verified Allergy
* Read and speak Swedish
Exclusion Criteria
* Current regular treatment with long-acting beta2-agonist
* Treatment with Singulair only or in combination with glucocorticoids
* Taking part in other research study
* Pregnancy or breast-feeding
* Unstable Asthma
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Stockholm
OTHER_GOV
Aerocrine AB
INDUSTRY
Phadia AB
UNKNOWN
Meda AB
UNKNOWN
The Swedish Research Council
OTHER_GOV
Swedish Council for Working Life and Social Research
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Uppsala University
OTHER
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Uppsala University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kjell Alving, PhD
Role: PRINCIPAL_INVESTIGATOR
Uppsala University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Runby Primary Health Care Center
Upplands Vasby, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20050166
Identifier Type: -
Identifier Source: org_study_id